Yulin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yulin Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Bei Wang
School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China
1 shared publication - Dongran Han
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
1 shared publication - Yixing Liu
School of Management, Beijing University of Chinese Medicine, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4820
Integrating Divergence-Based Proteomic Analysis and Directed Network Diffusion to Characterize Diagnosis-Anchored Molecular Variability at the Metabolic Syndrome–Migraine Interface
Metabolic syndrome (MetS) has been associated with migraine, but the prediagnostic phase and the molecular features preceding migraine onset remain unclear. We aimed to identify a diagnosis-anchored proteomic variability window and to characterize pathways, candidate bridge proteins, and druggable targets within a direction-consistent MetS-to-migraine molecular framework. We first assessed the association between baseline MetS and incident migraine in 452,471 UK Biobank participants using Cox models. We then conducted a nested proteomics case–control analysis stratified by MetS status and applied single-sample Jensen–Shannon divergence (sJSD), network proximity, directed diffusion, and drug–target proximity analyses. Baseline MetS was associated with a higher risk of incident migraine (hazard ratio 1.09, 95% confidence interval (CI) 1.01–1.18; p = 0.022). A diagnosis-anchored proteomic divergence pattern peaked 4.71–6.76 years before migraine diagnosis in the MetS stratum. The parallel within-stratum analysis in the NoMetS stratum showed no T2-centered peak. We identified 11 direction-consistent novel pathways, seven candidate bridge proteins spanning metabolic, endothelial, and brain tissues, and three candidate drugs. These findings support a diagnosis-stratified framework for studying MetS-related migraine and provide testable hypotheses for future mechanistic and pharmacological evaluation.
- 27 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4820
Open AccessIntegrating Divergence-Based Proteomic Analysis and Directed Network Diffusion to Characterize Diagnosis-Anchored Molecular Variability at the Metabolic Syndrome–Migraine Interface
Metabolic syndrome (MetS) has been associated with migraine, but the prediagnostic phase and the molecular features preceding migraine onset remain unclear. We aimed to identify a diagnosis-anchored proteomic variability window and to characterize pathways, candidate bridge proteins, and druggable targets within a direction-consistent MetS-to-migraine molecular framework. We first assessed the association between baseline MetS and incident migraine in 452,471 UK Biobank participants using Cox models. We then conducted a nested proteomics case–control analysis stratified by MetS status and applied single-sample Jensen–Shannon divergence (sJSD), network proximity, directed diffusion, and drug–target proximity analyses. Baseline MetS was associated with a higher risk of incident migraine (hazard ratio 1.09, 95% confidence interval (CI) 1.01–1.18; p = 0.022). A diagnosis-anchored proteomic divergence pattern peaked 4.71–6.76 years before migraine diagnosis in the MetS stratum. The parallel within-stratum analysis in the NoMetS stratum showed no T2-centered peak. We identified 11 direction-consistent novel pathways, seven candidate bridge proteins spanning metabolic, endothelial, and brain tissues, and three candidate drugs. These findings support a diagnosis-stratified framework for studying MetS-related migraine and provide testable hypotheses for future mechanistic and pharmacological evaluation.